Travere Therapeutics Inc

NASDAQ:TVTX   3:59:58 PM EDT
24.65
-0.38 (-1.52%)
Products, Strategic Combinations

Travere Therapeutics And Vifor Pharma Announce Licensing Agreement For The Commercialization Of Sparsentan In Europe, Australia And New Zealand

Published: 09/15/2021 20:11 GMT
Travere Therapeutics Inc (TVTX) - Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand.
Travere Therapeutics Inc - Vifor Pharma Obtains Exclusive Commercialization Rights for Sparsentan in Europe, Australia and New Zealand.
Travere Therapeutics - Co Receives $55 Million Upfront Payment.
Travere Therapeutics - Co is Eligible for Additional Regulatory & Commercial Milestones, As Well As Tiered Royalties on Net Sales.
Travere Therapeutics - Co is Eligible for Up to $135 Million in Payments Tied to Achievement of Certain Regulatory and Market Access Related Milestones.